Answers are grounded in this paper and cite their sources.
Levosalbutamol (LEV), the active R-enantiomer of salbutamol, has been proposed as an alternative to racemic salbutamol (RAC), potentially providing comparable bronchodilation with fewer systemic adverse effects.However, evidence regarding its comparative efficacy, safety, and healthcare resource utilization remains variable.The aim of this study was to systematically review the available evidence on the efficacy, safety, tolerability, and healthcare resource utilization associated with LEV compared with RAC in patients with asthma and wheezing.A systematic literature search was conducted in PubMed, Embase, Scopus, and the Cochrane Library from database inception through July 2026.Eligible randomized controlled trials and observational studies evaluating LEV in patients with asthma, wheezing, or related respiratory conditions were included.Two reviewers independently screened studies and extracted relevant data.Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I), and the Joanna Briggs Institute checklist, according to study design.Because of clinical and methodological heterogeneity, findings were synthesized narratively without quantitative meta-analysis.Eleven studies involving 2,701,152 participants met the inclusion criteria.Five randomized studies involving 334 participants directly compared LEV with RAC, while the remaining studies evaluated alternative delivery techniques, clinical effectiveness, or epidemiological and healthcare utilization outcomes.Direct comparative studies generally reported similar improvements in forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) between treatments.One study demonstrated greater improvement in peak expiratory flow rate with LEV (19.71 ± 7.23% vs. 15.57± 7.48%; p = 0.008).Two of three studies assessing symptom scores reported significantly lower post-treatment scores with LEV, whereas one found no significant difference.Safety findings were inconsistent: some comparative studies reported smaller increases in heart rate, better preservation of serum potassium, or fewer adverse events with LEV, while others found comparable safety outcomes.Observational and epidemiological studies provided additional information on clinical outcomes and healthcare utilization but did not establish comparative treatment benefits.Available comparative evidence suggests that LEV provides bronchodilator effects broadly similar to RAC, including in studies using lower doses of LEV.Some studies indicate potential benefits in symptom control and selected cardiovascular or metabolic safety outcomes; however, these findings are not consistent enough to establish overall safety superiority.Larger, adequately powered comparative trials using standardized dosing and longer follow-up are needed to clarify its clinical advantages and costeffectiveness.
No takes yet. Share an insight, caveat, or question.
Zaheer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: